Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

January 28th 2021

January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Preliminary Efficacy, Tolerability in Second-Line mCRC

January 27th 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Shorter Course of SBRT Proves Safe, Effective in High-Risk Prostate Cancer

January 27th 2021

January 27, 2021 — A shorter course of stereotactic body radiotherapy has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting.

Postoperative MRD Positivity Linked With Reduced RFS in CRC

January 26th 2021

January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.

NCCN Releases COVID-19 Vaccination Guidance for Patients With Cancer

January 22nd 2021

All patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the coronavirus disease 2019 vaccines that have been granted emergency use authorization from the FDA.